A number of other equities research analysts have also recently commented on VTGN. ValuEngine upgraded Vistagen Therapeutics from a hold rating to a buy rating in a research note on Thursday, November 1st. Zacks Investment Research cut Vistagen Therapeutics from a buy rating to a hold rating in a research note on Thursday, October 25th. Finally, Maxim Group set a $6.00 price target on Vistagen Therapeutics and gave the company a buy rating in a research note on Thursday, August 30th. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $8.30.
Vistagen Therapeutics stock opened at $2.10 on Friday. Vistagen Therapeutics has a one year low of $0.69 and a one year high of $2.65. The stock has a market capitalization of $65.22 million, a price-to-earnings ratio of -1.89 and a beta of -1.53.
Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Monday, October 29th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.13). As a group, equities research analysts predict that Vistagen Therapeutics will post -0.75 EPS for the current year.
About Vistagen Therapeutics
VistaGen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing medicines for depression and other central nervous system (CNS) disorders. The company's lead product candidate is AV-101, which is in Phase II development stage, an adjunctive treatment used for major depressive disorder.
Further Reading: Day Trading – Risk Worth the Reward?
Receive News & Ratings for Vistagen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vistagen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.